Methods for treating bladder and urethra dysfunction and disease
AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, Vanderbilt University, The Trustees of the University of Pennsylvania
InventorsEdwin Kerry Jackson, Lori Ann Birder, Amanda Sue Wolf-Johnston, Roger Dmochowski, Alan J. Wein
Life of this patent
Estimating the term…
Abstract
Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside phosphorylase (PNPase) inhibitor or purine nucleoside substrate is administered, such as 8-aminoguanine or forodesine.
Claims32
A method of treating bladder or urethra dysfunction or disease in a subject, comprising:
- selecting a subject with bladder or urethra dysfunction or disease;
- and
- administering to the subject a therapeutically effective amount of a purine nucleoside phosphorylase (PNPase) inhibitor or a PNPase purine nucleoside substrate, thereby treating the bladder or urethra dysfunction or disease.
(canceled)
(canceled)
15-16. (canceled)
19-20. (canceled)
A method of increasing bladder smooth muscle contractility or bladder wall volume in a subject, comprising
- selecting the subject in need of increased bladder smooth muscle contractility or decreased bladder wall volume, and
- administering to the subject a therapeutically effective amount of a purine nucleoside phosphorylase (PNPase) inhibitor or PNPase purine nucleoside substrate, thereby increasing bladder smooth muscle contractility or decreasing bladder wall volume in a subject.
22-33. (canceled)
(canceled)
A method of improving urethral function in a subject, comprising:
- selecting a subject with urethra dysfunction or disease;
- and
- administering to the subject a therapeutically effective amount of a purine nucleoside phosphorylase (PNPase) inhibitor or a PNPase purine nucleoside substrate, and
- wherein administration of the PNPase inhibitor or a PNPase purine nucleoside substrate:
- a) improves the morphology of the smooth or striated muscle in the urethra;
- b) decreases disruption of mitochondria in the urethra;
- or
- c) increases expression of alpha smooth muscle actin and cathepsin B in the urethra, thereby improving urethral function in the subject.
38-45. (canceled)
(canceled)
49-50. (canceled)
(canceled)
Dependencies are inferred from the claim text.